Overview

Safety And Efficacy Study Of Orally Administered DS102 In Patients With NAFLD

Status:
Completed
Trial end date:
2019-01-02
Target enrollment:
Participant gender:
Summary
The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered DS102 capsules versus placebo in the treatment of adult patients with Non Alcoholic Fatty Liver Disease (NAFLD)
Phase:
Phase 2
Details
Lead Sponsor:
Afimmune